Recently there have been several noteworthy developments within Astellas Pharma Inc. The company's CEO presented new strategies for their prescription medicine business. There is also a new head of US commercial, Michael Petroutsas, known for his proficient experience in the biotech industry. Additionally, Astellas has announced strategic collaborations and research agreements with organizations such as UMass Chan Medical School and Propella Therapeutics, along with a speculated joint venture with Takeda and Sumitomo Mitsui Banking. The US FDA has approved Astellas' combination therapy for bladder cancer, further simplifying the treatment process. The company has also secured approvals for its Eye Drug Izervay in Europe and Japan. However, it wasn't without setbacks, as the FDA rejected their gastric cancer drug due to manufacturing issues. Astellas has made changes within their management structure while focusing on cutting edge therapy ecosystems with YASKAWA, bi-specific antibody discoveries with Invenra, and patient-centric AI strategies.
Astellas Pharma Inc. News Analytics from Mon, 11 Oct 2021 07:00:00 GMT to Sat, 06 Jul 2024 08:05:15 GMT - Rating 8 - Innovation 8 - Information 7 - Rumor 5
